

---

# 2015 Report on Tuberculosis

---

## Research Funding Trends, 2005–2014:

---

### A Decade of Data

---

November 2015

Treatment Action Group

By Mike Frick




**TABLE 1****Changes in TB R&D Funding, 2005-2014**

| <b>YEAR</b> | <b>TOTAL TB R&amp;D INVESTMENT</b> | <b>CHANGE OVER PREVIOUS YEAR</b> | <b>CHANGE OVER PREVIOUS YEAR (%)</b> | <b>CHANGE OVER 2005</b> | <b>CHANGE OVER 2005 (%)</b> |
|-------------|------------------------------------|----------------------------------|--------------------------------------|-------------------------|-----------------------------|
| 2005        | \$358,476,537                      | N/A                              | N/A                                  | N/A                     | N/A                         |
| 2006        | \$418,928,300                      | \$60,451,763                     | 16.86                                | \$60,451,763            | 16.86                       |
| 2007        | \$478,343,421                      | \$59,415,121                     | 14.18                                | \$119,866,884           | 33.44                       |
| 2008        | \$494,576,235                      | \$16,232,815                     | 3.39                                 | \$136,099,698           | 37.97                       |
| 2009        | \$636,979,349                      | \$142,403,113                    | 28.79                                | \$278,502,812           | 77.69                       |
| 2010        | \$643,360,390                      | \$6,381,042                      | 1.00                                 | \$284,883,853           | 79.47                       |
| 2011        | \$675,328,887                      | \$31,968,497                     | 4.97                                 | \$316,852,350           | 88.39                       |
| 2012        | \$638,783,272                      | -\$36,545,615                    | -5.41                                | \$280,306,735           | 78.19                       |
| 2013        | \$686,303,295                      | \$47,520,023                     | 7.44                                 | \$327,826,758           | 91.45                       |
| 2014        | \$674,036,492                      | -\$12,266,804                    | -1.79                                | \$315,559,955           | 88.03                       |


**FIGURE 1**

## Annual *Global Plan* Research Funding Targets versus 2014 Funding



**FIGURE 2**

## Total TB R&D Funding, 2005-2014



**FIGURE 3**

## Total TB R&D Funding by Funder Category, 2014

**Total: \$674,036,492**




FIGURE 4

## Total TB R&D Funding by Funder Category, 2005-2014 (in Millions)





FIGURE 5

# Total TB R&D Funding by Research Category, 2005-2014 (in Millions)



**FIGURE 6**

## Total TB R&D Funding by Research Category, 2014

**Total: \$674,036,492**






FIGURE 7

## Basic Science: \$150,091,818




FIGURE 8

## Diagnostics: \$65,371,547




FIGURE 9

**Drugs: \$243,326,678**




FIGURE 10

## Vaccines: \$111,340,797




FIGURE 11

## Operational Research: \$52,828,217




FIGURE 12

## Pediatric TB R&D Funding by Research Category, 2014

Total: \$25,749,039





TABLE 3

## Pediatric TB R&D Funders by Rank, 2014

| 2014 RANK | FUNDING ORGANIZATION  | FUNDER TYPE | 2014 PEDIATRIC TB R&D FUNDING | PERCENTAGE OF TOTAL 2014 PEDIATRIC TB R&D FUNDING | TOTAL 2014 TB R&D FUNDING |
|-----------|---|-------------|-------------------------------|---|---------------------------|
| 1         | U.S. National Institutes of Health, Other Institutes and Centers (NIH Other ICs)                  | P           | \$6,077,122                   | 23.60   | \$37,988,748              |
| 2         | U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) | P           | \$4,170,434                   | 16.20   | \$168,013,064             |
| 3         | UNITAID   | M           | \$3,444,522                   | 13.38   | \$4,974,522               |
| 4         | European and Developing Countries Clinical Trials Partnership (EDCTP)                             | P           | \$2,840,939                   | 11.03   | \$6,564,042               |
| 5         | Macleods Pharmaceuticals  | C           | \$2,500,000                   | 9.71  | \$2,500,000               |
| 6         | Wellcome Trust  | F           | \$1,692,707                   | 6.57  | \$14,541,329              |
| 7         | U.K. Medical Research Council (U.K. MRC)  | P           | \$1,526,916                   | 5.93  | \$11,588,045              |
| 8         | Company V   | C           | \$1,103,696                   | 4.29  | \$15,361,586              |
| 9         | Bill & Melinda Gates Foundation   | F           | \$500,000                     | 1.94  | \$128,408,895             |
| 10        | Médecins Sans Frontières  | F           | \$317,758                     | 1.23  | \$936,253                 |
| 11        | U.K. National Institute for Health Research   | P           | \$289,869                     | 1.13  | \$3,705,204               |
| 12        | Canadian Institutes of Health Research  | P           | \$280,090                     | 1.09  | \$4,707,942               |
| 13        | French National Agency for AIDS Research (ANRS)   | P           | \$197,018                     | 0.77  | \$1,933,838               |
| 14        | French National Agency for Research (ANR)   | P           | \$153,671                     | 0.60  | \$2,865,585               |
| 15        | Colombia Ministry of Health and Social Protection   | P           | \$132,500                     | 0.51  | \$350,519                 |
| 16        | Thrasher Research Fund  | F           | \$110,000                     | 0.43  | \$110,000                 |
| 17        | UBS Optimus Foundation  | F           | \$96,934                      | 0.38  | \$96,934                  |
| 18        | Australian Research Council   | P           | \$84,726                      | 0.33  | \$1,019,066               |
| 19        | World Health Organization (WHO)   | M           | \$65,968                      | 0.26  | \$649,888                 |
| 20        | South African Medical Research Council (SAMRC)  | P           | \$51,808                      | 0.20  | \$2,515,493               |

**FIGURE 13**

## Total TB R&D Spending by PDPs, 2005-2014





**FIGURE 14**

## Country Contributions to TB R&D, 2014




TABLE 4

## Country Funding for R&D and TB R&D as a Percentage of GDP

| COUNTRY         | TB R&D<br>FUNDING 2014 | GDP 2014<br>(IN BILLIONS) | EXPENDITURE ON<br>R&D AS PERCENTAGE<br>OF GDP 2005–2014 | R&D EXPENDITURE<br>AS PERCENTAGE OF<br>GDP RANK ORDER | TB R&D EXPENDITURE<br>AS PERCENTAGE OF<br>GDP RANK ORDER |
|-----------------|------------------------|---------------------------|---|---|--|
| Singapore       | \$8,129,846            | \$308                     | 2.10  | 13  | 1  |
| United Kingdom  | \$44,540,305           | \$2,942                   | 1.72  | 15  | 2  |
| United States   | \$247,045,638          | \$17,419                  | 2.79  | 7   | 3  |
| South Africa    | \$4,743,304            | \$350                     | 0.76  | 20  | 4  |
| Switzerland     | \$7,834,737            | \$685                     | 2.87  | 6   | 5  |
| Denmark         | \$3,550,541            | \$342                     | 2.98  | 4   | 6  |
| New Zealand     | \$1,551,021            | \$188                     | 1.27  | 17  | 7  |
| Norway          | \$3,539,071            | \$500                     | 1.65  | 16  | 8  |
| India           | \$9,069,674            | \$2,067                   | 0.81  | 19  | 9  |
| Australia       | \$6,360,973            | \$1,454                   | 2.39  | 9   | 10   |
| The Netherlands | \$3,767,121            | \$870                     | 2.16  | 11  | 11   |
| Sweden          | \$2,122,923            | \$571                     | 3.41  | 2   | 12   |
| Canada          | \$5,826,492            | \$1,787                   | 1.73  | 14  | 13   |
| European Union  | \$41,976,394           | \$13,403                  | 2.14  | 12  | 14   |
| Germany         | \$11,684,001           | \$3,853                   | 2.92  | 5   | 15   |
| France          | \$8,049,793            | \$2,829                   | 2.26  | 10  | 16   |
| Taiwan*         | \$1,017,002            | \$530                     | 2.70  | 8   | 17   |
| Chile           | \$263,896              | \$258                     | 0.42  | 23  | 18   |
| Hong Kong       | \$293,302              | \$291                     | 0.75  | 21  | 19   |
| South Korea     | \$1,370,663            | \$1,410                   | 4.04  | 1   | 20   |
| Colombia        | \$350,519              | \$378                     | 0.17  | 24  | 21   |
| Japan           | \$2,730,101            | \$4,602                   | 3.39  | 3   | 22   |
| Brazil          | \$1,373,244            | \$2,346                   | 1.21  | 18  | 23   |
| Argentina       | \$132,406              | \$540                     | 0.65  | 22  | 24   |

\* Data on GDP taken from the National Statistics Bureau of the Republic of China (Taiwan); all other data on GDP and R&D expenditure come from the World Bank.